Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study

1Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018; 68: 394-24. doi: 10.3322/caac.21492 Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A. Global cancer statistics 2018 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 2018 68 394 24 10.3322/caac.21492Open DOISearch in Google Scholar

2Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87. doi: 10.1016/j.ejca.2018.07.005 Ferlay J Colombet M Soerjomataram I Dyba T Randi G Bettio M et al Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018 Eur J Cancer 2018 103 356 87 10.1016/j.ejca.2018.07.005Open DOISearch in Google Scholar

3Attard G, Parker C, Eeles R, Schröder F, Tomlins S, Tannock I, et al. Prostate cancer. Lancet 2016; 387: 70-82. doi: 10.1016/S0140-6736(14)61947-4 Attard G Parker C Eeles R Schröder F Tomlins S Tannock I et al Prostate cancer Lancet 2016 387 70 82 10.1016/S0140-6736(14)61947-4Open DOISearch in Google Scholar

4Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev 2016; 25: 16-27. doi: 10.1158/1055-9965 Torre LA Siegel RL Ward EM Jemal A Global cancer incidence and mortality rates and trends – an update Cancer Epidemiol Biomarkers Prev 2016 25 16 27 10.1158/1055-9965Open DOISearch in Google Scholar

5Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37. doi: 10.1016/j.eururo.2013.09.046 Heidenreich A Bastian PJ Bellmunt J Bolla M Joniau S van der Kwast T et al EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013 Eur Urol 2014 65 124 37 10.1016/j.eururo.2013.09.046Open DOISearch in Google Scholar

6Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375: 1425-37. doi: 10.1056/NEJMoa1606221 Donovan JL Hamdy FC Lane JA Mason M Metcalfe C Walsh E et al Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer N Engl J Med 2016 375 1425 37 10.1056/NEJMoa1606221Open DOISearch in Google Scholar

7Hamdy FC, Donovan JL, Lane JA. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415-24. doi: 10.1056/NEJMoa1606220 Hamdy FC Donovan JL Lane JA 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer N Engl J Med 2016 375 1415 24 10.1056/NEJMoa1606220Open DOISearch in Google Scholar

8Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-101. doi: 10.1016/s0360-3016(98)00438-6 Brenner DJ Hall EJ Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 1999 43 1095 101 10.1016/s0360-3016(98)00438-6Open DOISearch in Google Scholar

9Arcangeli S, Greco C. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? Nat Rev Urol 2016; 13: 400-8. doi: 10.1038/nrurol.2016.106 Arcangeli S Greco C Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? Nat Rev Urol 2016 13 400 8 10.1038/nrurol.2016.10627296648Open DOISearch in Google Scholar

10Zaorsky NG, Studenski MT, Dicker AP, Gomella L, Den R. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev 2013; 39: 212-8. doi: 10.1016/j.ctrv.2012.10.003 Zaorsky NG Studenski MT Dicker AP Gomella L Den R Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev 2013 39 212 8 10.1016/j.ctrv.2012.10.00323218442Open DOISearch in Google Scholar

11Dearnaley D, Syndikus I, Mossop H, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047-60. doi: 10.1016/S1470-2045(16)30102-4 Dearnaley D Syndikus I Mossop H Bidmead M Bloomfield D Clark C et al Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Lancet Oncol 2016 17 1047 60 10.1016/S1470-2045(16)30102-4Open DOISearch in Google Scholar

12Catton CN, Lukka H, Gu CS, Martin J, Supiot S, Chung P, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35: 1884-90. doi: 10.1200/JCO.2016.71.7397 Catton CN Lukka H Gu CS Martin J Supiot S Chung P et al Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer J Clin Oncol 2017 35 1884 90 10.1200/JCO.2016.71.7397Open DOISearch in Google Scholar

13Lee WR, Dignam JJ, Amin MB, Bruner D, Low D, Swanson G, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016; 34: 2325-32. doi: 10.1200/JCO.2016.67.0448 Lee WR Dignam JJ Amin MB Bruner D Low D Swanson G et al Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer J Clin Oncol 2016 34 2325 32 10.1200/JCO.2016.67.0448Open DOISearch in Google Scholar

14Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I, Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol Lond Engl 2013; 8: 84. doi: 10.1186/1748-717X-8-84 Aluwini S van Rooij P Hoogeman M Kirkels W Kolkman-Deurloo I Bangma C Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results Radiat Oncol Lond Engl 2013 8 84 10.1186/1748-717X-8-84Open DOISearch in Google Scholar

15Loblaw A, Cheung P, D’Alimonte L, Deabreu A, Mamedov A, Zhang L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013; 107: 153-8. doi: 10.1016/j.radonc.2013.03.022 Loblaw A Cheung P D’Alimonte L Deabreu A Mamedov A Zhang L et al Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes Radiother Oncol J Eur Soc Ther Radiol Oncol 2013 107 153 8 10.1016/j.radonc.2013.03.022Open DOISearch in Google Scholar

16King CR, Brooks JD, Gill H, Presti Jr J. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 877-82. doi: 10.1016/j.ijrobp.2010.11.054 King CR Brooks JD Gill H Presti Jr J Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer Int J Radiat Oncol Biol Phys 2012 82 877 82 10.1016/j.ijrobp.2010.11.054Open DOISearch in Google Scholar

17Jorgo K, Ágoston P, Szabó Z, Major T, Polgár Cs. [Use of gold radionuclide markers implanted into the prostate for image-guided radiotherapy in prostate cancer: side effects caused by the marker implantation]. [Hungarian]. Magy Onkol 2014; 58: 182-87. Jorgo K Ágoston P Szabó Z Major T Polgár Cs [Use of gold radionuclide markers implanted into the prostate for image-guided radiotherapy in prostate cancer: side effects caused by the marker implantation]. [Hungarian] Magy Onkol 2014 58 182 87Search in Google Scholar

18Jorgo K, Agoston P, Major T, Takácsi-Nagy Z, Polgár Cs. Transperineal gold marker implantation for image-guided external beam radiotherapy of prostate cancer. A single institution, prospective study. Strahlenther Onkol 2017; 193: 452-58. doi: 10.1007/s00066-017-1104-2. Jorgo K Agoston P Major T Takácsi-Nagy Z Polgár Cs Transperineal gold marker implantation for image-guided external beam radiotherapy of prostate cancer. A single institution, prospective study Strahlenther Onkol 2017 193 452 58 10.1007/s00066-017-1104-2Open DOISearch in Google Scholar

19D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72. doi: 10.1200/JCO.2003.01.075 D’Amico AV Moul J Carroll PR Sun L Lubeck D Chen M Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era J Clin Oncol 2003 21 2163 72 10.1200/JCO.2003.01.075Open DOISearch in Google Scholar

20Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 30: 1341-46. doi: 10.1016/0360-3016(95)00060-C Cox JD Stetz J Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 1995 30 1341 46 10.1016/0360-3016(95)00060-COpen DOISearch in Google Scholar

21Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what’s important. J Gen Intern Med 2000; 15: 694-701. doi: 10.1046/j.1525-1497.2000.90842.x Holmboe ES Concato J Treatment decisions for localized prostate cancer: asking men what’s important J Gen Intern Med 2000 15 694 701 10.1046/j.1525-1497.2000.90842.x149559711089712Open DOISearch in Google Scholar

22Dandapani SV, Sanda MG. Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. Semin Radiat Oncol 2008; 18: 67-72. doi: 10.1016/j.semradonc.2007.10.001 Dandapani SV Sanda MG Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer Semin Radiat Oncol 2008 18 67 72 10.1016/j.semradonc.2007.10.001Open DOISearch in Google Scholar

23Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman R. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. Am J Manag Care 2012; 18: e186-93. doi: 10.1200/JOP.2012.000548 Hodges JC Lotan Y Boike TP Benton R Barrier A Timmerman R Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer Am J Manag Care 2012 18 e186 93 10.1200/JOP.2012.000548Open DOISearch in Google Scholar

24Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019; 20: 1531-43. doi: 10.1016/S1470-2045(19)30569-8 Brand DH Tree AC Ostler P van der Voet H Loblaw A Chu W et al Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Lancet Oncol 2019 20 1531 43 10.1016/S1470-2045(19)30569-8Open DOISearch in Google Scholar

25Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019; 394: 385-95. doi: 10.1016/S0140-6736(19)31131-6 Widmark A Gunnlaugsson A Beckman L Thellenberg-Karlsson C Hoyer M Lagerlund M et al Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial Lancet 2019 394 385 95 10.1016/S0140-6736(19)31131-6Open DOISearch in Google Scholar

26Madsen BL, Hsi RA, Pham HT, Fowler J, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67: 1099-105. doi: 10.1016/j.ijrobp.2006.10.050 Madsen BL Hsi RA Pham HT Fowler J Esagui L Corman J Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results Int J Radiat Oncol Biol Phys 2007 67 1099 105 10.1016/j.ijrobp.2006.10.05017336216Open DOISearch in Google Scholar

27Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010; 10: 1. doi: 10.1186/1471-2490-10-1 Katz AJ Santoro M Ashley R Diblasio F Witten M et al Stereotactic body radiotherapy for organ-confined prostate cancer BMC Urol 2010 10 1 10.1186/1471-2490-10-1283188820122161Open DOISearch in Google Scholar

28Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie X, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 2020-26. doi: 10.1200/JCO.2010.31.4377 Boike TP Lotan Y Cho LC Brindle J DeRose P Xie X et al Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer J Clin Oncol 2011 29 2020 26 10.1200/JCO.2010.31.4377313854621464418Open DOISearch in Google Scholar

29Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011; 6: 3. doi: 10.1186/1748-717X-6-3 Freeman DE King CR Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes Radiat Oncol 2011 6 3 10.1186/1748-717X-6-3302274021219625Open DOISearch in Google Scholar

30Jabbari S, Weinberg VK, Kaprealian T, Hsu I, Ma L, Chuang C, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012; 82: 228-34. doi: 10.1016/j.ijrobp.2010.10.026 Jabbari S Weinberg VK Kaprealian T Hsu I Ma L Chuang C et al Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response Int J Radiat Oncol Biol Phys 2012 82 228 34 10.1016/j.ijrobp.2010.10.02621183287Open DOISearch in Google Scholar

31McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom H, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012; 118: 3681-90. doi: 10.1002/cncr.26699 McBride SM Wong DS Dombrowski JJ Harkins B Tapella P Hanscom H et al Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial Cancer 2012 118 3681 90 10.1002/cncr.2669922170628Open DOISearch in Google Scholar

32Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013; 13: 49. doi: 10.1186/1471-2490-13-49 Bolzicco G Favretto MS Satariano N Scremin E Tambone C Tasca A A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy BMC Urol 2013 13 49 10.1186/1471-2490-13-49401654224134138Open DOISearch in Google Scholar

33Oliai C, Lanciano R, Sprandio B, Yang J, Lamond J, Arrigo S, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol 2013; 2: 63-70. doi: 10.1007/s13566-012-0067-2 Oliai C Lanciano R Sprandio B Yang J Lamond J Arrigo S et al Stereotactic body radiation therapy for the primary treatment of localized prostate cancer J Radiat Oncol 2013 2 63 70 10.1007/s13566-012-0067-2359482423504305Open DOISearch in Google Scholar

34Mantz C. A Phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and realtime target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol 2014; 4: 279. doi: 10.3389/fonc.2014.00279 Mantz C A Phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and realtime target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up Front Oncol 2014 4 279 10.3389/fonc.2014.00279423183725452933Open DOISearch in Google Scholar

35Chen LN, Suy S, Wang H, Bhagat A, Woo J, Moures R, et al. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 2014; 9: 148. doi: 10.1186/1748-717X-9-148 Chen LN Suy S Wang H Bhagat A Woo J Moures R et al Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer Radiat Oncol 2014 9 148 10.1186/1748-717X-9-148408336224966110Open DOISearch in Google Scholar

36Anwar M, Weinberg V, Seymour Z, Hsu J, Roach M 3rd, Gottschalk A. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol 2016; 11: 8. doi: 10.1186/s13014-016-0585-y Anwar M Weinberg V Seymour Z Hsu J Roach M 3rd Gottschalk A Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer Radiat Oncol 2016 11 8 10.1186/s13014-016-0585-y472106326792201Open DOISearch in Google Scholar

37Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh B, Brindle J, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer 2016; 59: 142-51. doi: 10.1016/j.ejca.2016.02.014 Hannan R Tumati V Xie XJ Cho LC Kavanagh B Brindle J et al Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial Eur J Cancer 2016 59 142 51 10.1016/j.ejca.2016.02.01427035363Open DOISearch in Google Scholar

38Murthy V, Sinha S, Kannan S, Datta D, Das R, Bakshi G, et al. Safety of prostate stereotactic body radiation therapy after Transurethral Resection of Prostate (TURP): A propensity score matched pair analysis. Pract Radiat Oncol 2019; 5: 347-53. doi: 10.1016/j.prro.2019.04.003 Murthy V Sinha S Kannan S Datta D Das R Bakshi G et al Safety of prostate stereotactic body radiation therapy after Transurethral Resection of Prostate (TURP): A propensity score matched pair analysis Pract Radiat Oncol 2019 5 347 53 10.1016/j.prro.2019.04.00330978467Open DOISearch in Google Scholar

39Wang K, Chen RC, Kane B, Medbery C, Underhill K, Gray J, et al. Patient and dosimetric predictors of genitourinary and bowel quality of life after prostate SBRT: Secondary analysis of a multi-institutional trial. Int J Radiat Oncol Biol Phys 2018; 102: 1430-37. doi: 10.1016/j.ijrobp.2018.07.191 Wang K Chen RC Kane B Medbery C Underhill K Gray J et al Patient and dosimetric predictors of genitourinary and bowel quality of life after prostate SBRT: Secondary analysis of a multi-institutional trial Int J Radiat Oncol Biol Phys 2018 102 1430 37 10.1016/j.ijrobp.2018.07.19130056080Open DOISearch in Google Scholar

40Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013; 13: 49. doi: 10.1186/1471-2490-13-49 Bolzicco G Favretto MS Satariano N Scremin E Tambone C Tasca A A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy BMC Urol 2013 13 49 10.1186/1471-2490-13-49Open DOISearch in Google Scholar

41Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol 2014; 4: 301. doi: 10.3389/ fonc.2014.00301 Katz AJ Kang J Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study Front Oncol 2014 4 301 10.3389/fonc.2014.00301421138525389521Open DOISearch in Google Scholar

42Gurka MK, Chen LN, Bhagat A, Moures R, Kim SJ, Yung T, et al. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 2015; 10: 44. doi: 10.1186/s13014-015-0351-6 Gurka MK Chen LN Bhagat A Moures R Kim SJ Yung T et al Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer Radiat Oncol 2015 10 44 10.1186/s13014-015-0351-6435886625890265Open DOISearch in Google Scholar